Willis Investment Counsel’s Summit Therapeutics SMMT Stock Holding History

Willis Investment Counsel’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$146K	Hold	10,000	–	–	0.01%	122
2026 Q1	$190K	Sell	10,000 -390	-4%	-$6.31K	0.01%	120
2025 Q4	$182K	Buy	10,390 +390	+4%	+$7.34K	0.01%	127
2025 Q3	$207K	Hold	10,000	–	–	0.01%	121
2025 Q2	$213K	Hold	10,000	–	–	0.01%	114
2025 Q1	$193K	Hold	10,000	–	–	0.01%	115
2024 Q4	$178K	Hold	10,000	–	–	0.01%	114
2024 Q3	$219K	Buy	+10,000	New	+$140K	0.01%	110

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Willis Investment Counsel's SMMT Position: Q2 2026 in Review

Willis Investment Counsel held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 10,000 shares worth $146K. The position accounts for 0.01% of the portfolio, ranked #122.

Willis Investment Counsel first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $219K in Q3 2024. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Willis Investment Counsel held 10,000 shares of Summit Therapeutics worth $146K as of Q2 2026.
Willis Investment Counsel left its Summit Therapeutics share count unchanged in Q2 2026.
Summit Therapeutics made up 0.01% of Willis Investment Counsel's portfolio in Q2 2026, its #122 holding.
Willis Investment Counsel first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
Willis Investment Counsel's Summit Therapeutics position peaked at $219K in Q3 2024.
243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Willis Investment Counsel's 13F filing for Q2 2026, filed 3 Aug 2026.